申请人:SUMITOMO DAINIPPON PHARMA CO., LTD.
公开号:US10703755B2
公开(公告)日:2020-07-07
The present invention relates to a substituted purine derivative of formula (1) wherein R1 is alkoxy or the like, R2 is alkyl or the like, Ring Q1 is aryl or the like, W1 is alkylene or the like, Ring Q2 is aromatic carbocyclyl or the like, n is 1-4, R3 is hydrogen atom or the like, X1 is single bond or the like, W2 is alkylene or the like, and R4 is hydrogen atom or the like, or a pharmaceutically acceptable salt thereof, which has a potent inhibitory effect against TLR7, and thereby is useful for treating autoimmune disease.
本发明涉及式(1)的取代嘌呤衍生物,其中R1是烷氧基或类似物,R2是烷基或类似物,环Q1是芳基或类似物,W1是亚烷基或类似物,环Q2是芳香族羰基或类似物,n是1-4、R3 是氢原子或类似物,X1 是单键或类似物,W2 是亚烷基或类似物,R4 是氢原子或类似物,或其药学上可接受的盐,对 TLR7 具有强效抑制作用,因此可用于治疗自身免疫性疾病。